Arrayit Pursuing PMA from FDA for OvaDx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Microarray firm Arrayit today said that it will be seeking pre-market approval by the US Food and Drug Administration for its OvaDx ovarian cancer test.

In a statement, the Sunnyvale, Calif., firm said that though the PMA process is more stringent than the 510(k) route, it believes it can receive Class III PMA approval for the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.